Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned, "<u>Version with markings to show changes made</u>."

REMARKS

Claims 11, 12, and 15, are pending. Claims 11, 12, and 15 are rejected.

Claim 11 is amended as suggested by the Examiner. Applicants believe no new matter is added by way of amendment.

Applicants note that the Petition to Correct Inventorship under 37 C.F.R. 1.48(b), filed on July 31, 2002, has been accepted and entered.

I. Rejection of Claims 11, 12, and 15, under 35 U.S.C. 112, Second Paragraph.

The Examiner rejected Claims 11, 12, and 15, under 35 U.S.C. 112, second paragraph. As amended, Claim 11 recites the language suggested by the Examiner. Applicants believe that amended Claim 11 is now in allowable form as are Claims 12 and 15, which depend from Claim 11.

In view of the foregoing amendment, Applicants submit that the rejection of Claims 11, 12, and 15 under 35 U.S.C. 112, second paragraph, is overcome. Withdrawal of this rejection is respectfully requested.

Conclusion

Applicants' current response is believed to be a complete reply to all the outstanding issues of the latest Office Action. Further, the present response is a bona fide effort to place the application in condition for allowance or in better form for appeal. Accordingly, Applicants respectfully request reconsideration and passage of the amended claims to allowance at the earliest possible convenience. Should the Examiner deem allowance inappropriate at this time, Applicants respectfully request an interview be granted with the undersigned to consider any issues.

Applicants believe that no fees are due with this timely response. Should this not be the case, the Commissioner is hereby authorized to debit and fees or credit any overpayments to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

Sheela Mohan-Peterson

Attorney for Applicants

Reg. No. 41,201

DNAX Research, Inc. 901 California Avenue Palo Alto, California 94304-1104

Main:

(650) 496-6400

Direct:

(650) 496-1244

Fax:

(650) 496-1200

VERSIONS WITH MARKINGS TO SHOW CHANGES MADE

In the claims:

11. (Amended Twice) A binding compound comprising an antibody binding site from an antibody which specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

ZLOT, et al. USSN: 09/713,098